Page 8 - Sun Pharma

Sun Pharma Q3 Preview: Profits may jump 13%, revenues to rise 10% YoY

According to brokerage estimates compiled by Business Standard, Sun Pharma may see its average revenue rise by 9.51 per cent year-on-year (Y-o-Y) to Rs 13,313 crore as against Rs 12,156 crore

Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics

The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice

Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

According to a regulatory filing with BSE, the agreement was signed on December 31, 2024, with the transaction expected to be completed by January 31, 2025

Stocks to Watch, January 1, 2025: Auto stocks, ITC, Sun Pharma, Piramal Ent

The previous session closed out 2024 with mixed sentiments. Despite a strong recovery from intraday lows, the benchmarks ended in the red, weighed down by losses in IT & select banking shares

Nandish Shah of HDFC Sec suggests 'Bull Spread' strategy on Sun Pharma

Long rollover is seen in the Sun Pharma Futures to the January series, where we have seen 34 per cent rise in the open interest with price rising by 1.23 per cent

Despite short-term blip, Sun Pharma remains favourite among investors

According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Stocks to Watch, Nov 29: SBI, PC Jeweller, Nazara Tech, Adani Group shares

Stocks to Watch, Nov 29: Here are few stocks that will remain in focus for today's session

Sun Pharma's Leqselvi launch in US faces legal roadblock; analysts cautious

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company wins its appeal, or up to two years if it loses the case entirely

Sun Pharma slips 5% as US court bars it from launching alopecia drug

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the line, ICICI Securities expects some negative impact on the company

Analysts offer mixed views on Sun Pharma's near term growth; revise target

Shares of Sun Pharmaceuticals, the biggest pharmaceutical company of India fell 1.71 per cent at Rs 1870 per share on the BSE after brokerages offered mixed reviews post Q2

Sun Pharma Q2 profit up 28% on strong domestic, emerging mkts performance

The company launched 14 new products in India this quarter

Sun Pharma Q2FY25 results: Net profit rises 28% to Rs 3,040 crore

Sun Pharmaceutical Industries on Monday reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in the September quarter. The drug major had posted a net profit of Rs 2,375 crore in the July-September quarter of last fiscal. Total income rose to Rs 13,645 crore in the second quarter compared to Rs 12,486 crore in the year-ago period, the Mumbai-based drug major said in a regulatory filing. "Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercialising late stage candidate Fibromun, upon approval," Dilip Shanghvi, Chairman and Managing Director of the company, said. With Fibromun, the company's product basket for dermatologists has expanded further, he added. "We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market," Shanghvi said. Shares of the company were trading 2.22 per cent higher at Rs 1,901.55 apiece on the BSE.

Q2 results today: Airtel, Adani Power and BHEL among 168 to post earnings

Q2FY25 company results: Indian Oil, Ambuja Cements, Aditya Birla Sun Life AMC, Sun Pharma and more will report their second-quarter earnings on October 28

Sun Pharma Q2 Preview: Profit may rise by 19%, R&D spends to impact margins

Analysts expect Sun Pharma to register double digit growth in the topline and bottomline driven by specialty sales

Navratri 2024: 9 stocks for your equity portfolio for sparkling returns

ONGC, Oil India, GNFC, Tata Chemicals and Sun Pharma are among the 9 stocks that could rally up to 20%, suggests technical charts. Check key support and resistance levels for these stocks here.

Sun Pharma signs licensing pact with Philogen for cancer medication

Sun Pharmaceutical Industries on Tuesday said it has inked a global licensing pact with Italian-Swiss firm Philogen for an anti-cancer drug. As per the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun, a speciality product of Philogen. Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma. As per the pact, Philogen will complete the ongoing pivotal clinical trials for the product, pursue marketing authorisation with regulatory authorities, and manufacture commercial supplies, the Mumbai-based drug major said in a statement. Sun Pharma will be responsible for commercialisation activities, it added. The two partner companies will share post-commercialisation economics in about 45(Philogen):55(Sun Pharma) ratio, Sun Pharma said. The company did not disclose other financial terms. "Fibromun's progress through development has been qui

Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.

UBS fears slowdown in India, US pharma markets; gives 'Sell' on 4 stocks

As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics

Sun Pharma hits 52-week high on launch of skin infection drug 'Starizo'

Starizo is used to treat Acute Bacterial Skin and Skin Structure Infection.